A Phase 4 interventional study of Vyleesi (Bremelanotide Injection) in Lactating Mother, sponsored by Cosette Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Cosette Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this clinical trial performed with Vyleesi (Bremelanotide Injection) are:
This open-label, pharmacokinetic (PK) study will be performed in 10 healthy lactating female subjects between 10 days and 6 months post-partum (inclusive). The maximum duration of subject participation in the study will be approximately 29 days, consisting of 3-week Screening period, a 1 day treatment period, and up to a 7 day follow-up period.
This is the only study on the registry with Cosette Pharmaceuticals, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Main Criteria):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One dose of BMT 1.75 mg SC on Day 1
Drug: Vyleesi (Bremelanotide Injection)
Single dose of BMT 1.75 mg SC on Day 1
Levels of Bremelanotide (BMT) in Breast Milk Over 24h After Administration of Vyleesi
The levels/concentrations of bremelanotide (BMT) will be measured in breast milk samples collected at different timepoints up to 24h from lactating women who receive a single dose of Vyleesi (BMT 1.75 mg SC).
Time frame: 24 hours
Area under the curve from time 0 to end of dosing interval (AUCtau) for BMT in Breast Milk
Time frame: 24 hours
Maximum observed concentration (Cmax) of BMT in breast milk
Time frame: 24 hours
Time to reach Cmax of BMT in breast milk (Tmax)
Time frame: 24 hours
Terminal half-life of BMT in breast milk (t1/2)
Time frame: 24 hours
Levels of Bremelanotide (BMT) in Plasma Over 24h After Administration of Vyleesi
Time frame: 24 hours
Area under the curve from time 0 to end of dosing interval (AUCtau) for BMT in Plasma
Time frame: 24 hours
Maximum observed concentration (Cmax) of BMT in Plasma
Time frame: 24 hours
Time to reach Cmax of BMT in Plasma (Tmax)
Time frame: 24 hours
Milk:plasma ratio (M/P) of BMT Levels
Time frame: 24 hours
Ran from Jul 2025 to primary completion in Nov 2025, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bremelanotide